After Karuna's acquisition, former CEO lands new gig at Cambridge biotech

1d ago, source:

Bill Meury is now leading a clinical-stage Cambridge company developing treatments for cardiovascular diseases.

Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position

1mon ago, source: InvestingChannel on MSN

Amalthea Fund featured stocks like Karuna Therapeutics, Inc. (NASDAQ:KRTX) in the fourth quarter 2023 investor letter.

Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better

5d ago, source:

AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. But the latest results from Cerevel’s ...

Karuna Therapeutics Inc KRTX

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PureTech's newest biotech spinout represents a shift from the past

1mon ago, source: The Business Journals

Boston-based PureTech Health plc believes it hit on a winning formula when it developed and spun out Karuna Therapeutics Inc. Just this week, Bristol Myers Squibb (NYSE: BMY) completed its $14 ...

Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics

14d ago, source: FierceBiotech

Just months after Bristol Myers Squibb boarded Karuna Therapeutics for its much-hyped schizophrenia drug, the biotech’s leadership has set sail in a new venture. Seaport Therapeutics is ...

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

1mon ago, source: Morningstar

today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq ...

Anthos Therapeutics Announces Appointment of Bill Meury as CEO

1d ago, source:

Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone ...

Seaport Therapeutics has $100 million to develop new ways to treat mental disorders

14d ago, source: The Boston Globe

The team behind Karuna Therapeutics, the Boston biotech that was bought by drug giant Bristol Myers Squibb in a $14 billion deal in December, launched another company on Tuesday called Seaport ...

Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells

15d ago, source: STAT

The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on Tuesday rolled out another neuropsychiatric-focused biotech, called Seaport Therapeutics.

Karuna Therapeutics set to merge with Bristol-Myers Squibb

1mon ago, source: Investing

Karuna Therapeutics Inc . (NASDAQ: NASDAQ:KRTX) is on the cusp of becoming a wholly owned subsidiary of Bristol-Myers Squibb (NYSE: NYSE:BMY), as a key regulatory hurdle has been cleared. The waiting ...

Karuna Therapeutics Inc (KRTX)

1mon ago, source: Investing

Investing in mid-cap stocks is essential for investors who prefer a diversified portfolio. These stocks offer a middle ground with regard to the risks and rewards when compared to ...